摘要
目的:探讨康复新液辅助抗结核化疗方案治疗肠结核的疗效及对炎症因子、T淋巴细胞亚群的影响。方法:选取2018年2月至2019年10月该院收治的肠结核患者92例,随机分为研究组(46例)和对照组(46例)。对照组患者给予常规基础治疗+2HRZE/4HR抗结核化疗方案,研究组患者在对照组的基础上加用康复新液。观察两组患者的临床疗效,并比较两组患者治疗前后炎症因子[肿瘤坏死因子α(TNF-α)、白细胞介素1(IL-1)、白细胞介素10(IL-10)和C反应蛋白(CRP)]水平及T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)和CD4^(+)/CD8^(+))水平变化,记录两组患者不良反应发生情况。结果:研究组患者的总有效率为89.13%(41/46),显著高于对照组的69.57%(32/46),差异有统计学意义(P<0.05)。治疗后,两组患者血清TNF-α、IL-1、IL-10、CRP和CD8^(+)水平均较治疗前显著降低,且研究组患者较对照组明显更低,差异均有统计学意义(P<0.05);治疗后,两组患者CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)水平均较治疗前显著升高,且研究组患者较对照组明显更高,差异均有统计学意义(P<0.05)。研究组、对照组患者的总不良反应发生率分别为32.61%(15/46)、28.26%(13/46),差异无统计学意义(χ^(2)=0.205,P=0.650)。结论:采用康复新液辅助抗结核化疗方案治疗肠结核,可显著降低患者机体炎症因子水平,改善细胞免疫系统,提高临床效果,且安全性较好。
OBJECTIVE:To probe into the efficacy of Kangfuxin liquid in adjuvant anti-tuberculous chemotherapy for intestinal tuberculosis and its effects on inflammatory factors and T-lymphocyte subsets.METHODS:Totally 92 patients with intestinal tuberculosis admitted into this hospital from Feb.2018 to Oct.2019 were extracted to be randomly divided into the study group(n=46)and the control group(n=46).The control group was given conventional basic treatment+2HRZE/4HR anti-tuberculosis chemotherapy regimen,while the study group received Kangfuxin liquid on the basis of the control group.The clinical efficacy of two groups were compared,and the changes of levels of inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-1(IL-1),interleukin-10(IL-10),Creactive protein(CRP)]and T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))before and after treatment were compared between two groups.Adverse drug reactions of two groups were compared.RESULTS:The total effective rate in the study group was 89.13%(41/46),significantly higher than 69.57%(32/46)in the control group,the difference was statistically significant(P<0.05).After treatment,the levels of TNF-α,IL-1,IL-10,CRP and CD8^(+) in two groups were significantly lower than those before treatment,and the study group was significantly lower than the control group,with statistically significant differences(P<0.05).After treatment,the levels of CD3^(+),CD4^(+) and CD4^(+)/CD8^(+) in two groups were significantly higher than those before treatment,and the study group was higher than the control group,the differences were statistically significant(P<0.05).The incidence of total adverse drug reactions in the study group and the control group were respectively 32.61%(15/46)and 28.26%(13/46),with statistically significant differences(χ^(2)=0.205,P=0.650).CONCLUSIONS:Kangfuxin liquid in adjuvant anti-tuberculous chemotherapy for intestinal tuberculosis can significantly reduce the level of inflammatory factors,improve the cellular immune system,and enhance the clinic
作者
张敏
陈庆
魏书青
马静
高金昙
ZHANG Min;CHEN Qing;WEI Shuqing;MA Jing;GAO Jintan(Dept.of Gastroenterology,Hebei Chest Hospital,Shijiazhuang 050041,China)
出处
《中国医院用药评价与分析》
2022年第1期29-31,37,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
河北省中医药管理局科研项目(No.2020159,No.2020158,No.2017098)。
关键词
康复新液
抗结核化疗
肠结核
炎症因子
T淋巴细胞亚群
Kangfuxin liquid
Anti-tuberculous chemotherapy
Intestinal tuberculosis
Inflammatory factors
T lymphocyte subsets
